| VAFAX | VIGAX | VAFAX / VIGAX | |
| Total Expense Ratio | 0.96 | 0.05 | 1,920% |
| Annual Report Gross Expense Ratio | 0.96 | 0.05 | 1,920% |
| Fund Existence | 20 years | 25 years | - |
| Gain YTD | 8.927 | 15.297 | 58% |
| Front Load | 6% | N/A | - |
| Min. Initial Investment | 1000 | 3000 | 33% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 17.3B | 357B | 5% |
| Annual Yield % from dividends | 0.00 | 0.40 | - |
| Returns for 1 year | 5.65 | 17.18 | 33% |
| Returns for 3 years | 77.12 | 109.12 | 71% |
| Returns for 5 years | 9.64 | 99.45 | 10% |
| Returns for 10 years | 80.01 | 332.05 | 24% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| GLTR | 176.46 | 0.52 | +0.30% |
| abrdn Physical PrecMtlBsk Shrs ETF | |||
| QCAP | 23.35 | 0.03 | +0.11% |
| FT Vest Nasdaq-100 Cnsrv Buffr ETF - Apr | |||
| USVN | 48.80 | 0.06 | +0.11% |
| F/m US Treasury 7 Year Note ETF | |||
| REVS | 27.59 | -0.05 | -0.18% |
| Columbia Research Enhanced Value ETF | |||
| BBH | 189.89 | -0.62 | -0.33% |
| VanEck Biotech ETF | |||